12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
It happens all the time! The owner-contractor agreement contains a “no damages for delay” clause; ...
Read More >
On May 21, 2020, the Securities and Exchange Commission announced rule and form amendments that will...
Read More >
California Appellate Court Provides Guidance - Passthrough payments negotiated prior to the dissolu...
Read More >
The Colorado Department of Labor and Employment (the “Department”) has published proposed regulati...
Read More >
On August 7, 2019, U.S. Immigration and Customs Enforcement’s (ICE) Homeland Security Investigation...
Read More >
The National Labor Relations Board (the "NLRB" or "Board") issued a Notice of Proposed Rulemaking on...
Read More >